Literature DB >> 1737341

Localization of shed human tumor gangliosides: association with serum lipoproteins.

L A Valentino1, S Ladisch.   

Abstract

Tumor gangliosides are biologically active (immunosuppressive and tumor-enhancing) cell surface molecules which are shed into the circulation in vivo. However, the mechanism of transport of these molecules (i.e., in solution or bound to proteins or other lipids) is not known. To resolve this question we traced, by direct chemical detection, the serum localization of a specific human tumor ganglioside, GD2, shed by neuroblastoma cells. Sera from patients with tumors were separated into the lipoprotein fractions [very low-density lipoprotein, low-density lipoprotein (LDL), and high-density lipoprotein] and lipoprotein-depleted serum. All three lipoprotein fractions contained GD2. 73% of the total GD2 was present in the LDL fraction, while very low-density lipoprotein and high-density lipoprotein contained 21 and 6%, respectively. Significantly, lipoprotein-depleted serum, which would contain both albumin-bound and free ganglioside, was devoid of GD2. Thus, shed neuroblastoma tumor gangliosides are exclusively associated with the serum lipoprotein (and predominantly LDL) fractions in vivo. These findings have implications for the immunological detection of these molecules and the development of approaches to their removal.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1737341

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Serum immunoassay of a small cell lung cancer associated ganglioside: development of a sensitive scintillation proximity assay.

Authors:  T Pallesen; A Vangsted; L Drivsholm; H Clausen; J Zeuthen; H Wallin
Journal:  Glycoconj J       Date:  1992-12       Impact factor: 2.916

2.  Evaluation of the efficiency of an assay procedure for gangliosides in human serum.

Authors:  E Negroni; V Chigorno; G Tettamanti; S Sonnino
Journal:  Glycoconj J       Date:  1996-06       Impact factor: 2.916

3.  Structural characterization and in vivo immunosuppressive activity of neuroblastoma GD2.

Authors:  R Li; D Gage; R McKallip; S Ladisch
Journal:  Glycoconj J       Date:  1996-06       Impact factor: 2.916

Review 4.  Unraveling the complexities of the HDL lipidome.

Authors:  Anatol Kontush; Marie Lhomme; M John Chapman
Journal:  J Lipid Res       Date:  2013-03-30       Impact factor: 5.922

5.  Quantitative studies of monoclonal antibody targeting to disialoganglioside GD2 in human brain tumors.

Authors:  E Arbit; N K Cheung; S D Yeh; F Daghighian; J J Zhang; C Cordon-Cardo; K Pentlow; A Canete; R Finn; S M Larson
Journal:  Eur J Nucl Med       Date:  1995-05

6.  Thematic review series: sphingolipids. Ganglioside GM3 suppresses the proangiogenic effects of vascular endothelial growth factor and ganglioside GD1a.

Authors:  Purna Mukherjee; Anthony C Faber; Laura M Shelton; Rena C Baek; Thomas C Chiles; Thomas N Seyfried
Journal:  J Lipid Res       Date:  2008-02-20       Impact factor: 5.922

7.  Inhibition of immune cell proliferation and cytokine production by lipoprotein-bound gangliosides.

Authors:  C Dumontet; A Rebbaa; J Bienvenu; J Portoukalian
Journal:  Cancer Immunol Immunother       Date:  1994-05       Impact factor: 6.968

8.  Gangliosides regulate tumor cell adhesion to collagen.

Authors:  Tamara Kazarian; Adnan A Jabbar; Fei-Qui Wen; Dharmesh A Patel; Leonard A Valentino
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

9.  Interaction of fibroblast growth factor-2 (FGF-2) with free gangliosides: biochemical characterization and biological consequences in endothelial cell cultures.

Authors:  M Rusnati; E Tanghetti; C Urbinati; G Tulipano; S Marchesini; M Ziche; M Presta
Journal:  Mol Biol Cell       Date:  1999-02       Impact factor: 4.138

10.  Gangliosides are potent immunosuppressors of IL-2-mediated T-cell proliferation in a low protein environment.

Authors:  P Lu; F J Sharom
Journal:  Immunology       Date:  1995-11       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.